Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Daily News

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

Yael L. Maxwell

July 05, 2016

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

State of the (Drug-Eluting) Stent: World-Wide Usage, New Perspectives in Stable CAD, and Remaining Challenges

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi

September 14, 2014

Presentation TCT 2014

The Concept of the COBRA PzF-Shielded Stent

Presenter: Renu Virmani, Donald Cutlip

September 13, 2014

Presentation TCT 2013

Implications of Periprocedural CKMB and Troponin Elevations After PCI: A Critical Appraisal

Presenter: Donald Cutlip

October 28, 2013

Presentation TCT 2012

What's Needed for... Label Expansion (Bifurcations, Left Main, AMI, CTO, etc.)?

Presenter: Donald Cutlip

October 25, 2012

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Yael L. Maxwell

March 06, 2012

Advertisement

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

New Biomarker-Based Risk Score Performs Well in ACS

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

State of the (Drug-Eluting) Stent: World-Wide Usage, New Perspectives in Stable CAD, and Remaining Challenges

The Concept of the COBRA PzF-Shielded Stent

Implications of Periprocedural CKMB and Troponin Elevations After PCI: A Critical Appraisal

What's Needed for... Label Expansion (Bifurcations, Left Main, AMI, CTO, etc.)?

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content